Mechanism of Action

Modulates GABA-A receptor system (similar mechanism to benzodiazepines but without sedation/tolerance/dependence). Normalizes serotonin and dopamine receptors, enhances BDNF expression, immunomodulatory effects including interferon induction.

Clinical Use

Anxiety, cognitive enhancement, stress resilience, PTSD adjunct. Nasal/subcutaneous administration. Compounding use in integrative medicine.

Contraindications

Mania/bipolar disorder. Seizure disorders (theoretical). Active autoimmune conditions.

Evidence Summary

Approved in Russia as anxiolytic/nootropic. Multiple Russian RCTs in GAD and cognitive decline. Limited independent Western replication.

Key Studies
  • 1.Semenova et al., Bull Exp Biol Med 2010 — anxiety reduction RCT, significant vs control
  • 2.Volkova et al., Bull Exp Biol Med 2016 — BDNF modulation and neuroprotective signaling
  • 3.Zozulya et al., Bull Exp Biol Med 2001 — mechanism of action and receptor interactions
Evidence Gaps

Most evidence from Russian clinical practice. Limited independent Western replication. Nasal spray delivery raises bioavailability questions.

Emerging Research

Growing Western adoption for anxiety management without benzodiazepine risks. Immunomodulatory and antiviral properties post-COVID.

iRemedy Sourcing Status
AVAILABLE
Available as compounding API

iRemedy is a 50-state licensed, NABP-accredited wholesale distributor. Peptides supplied with full CoA, DSCSA serialization, and UPS Healthcare cold chain logistics. Wholesale to licensed healthcare facilities and compounding pharmacies only.

← Back to Peptide Library ← Previous: Retatrutide Next: Semaglutide →
Request Peptide Catalog →